Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol
- *Corresponding Author:
- Athanasios Manolis
41, Thassou street, 16672
Tel: +30 2108970477
Fax: +30 2108923209
Received date May 11, 2016; Accepted date May 30, 2016; Published date June 06, 2016
Citation: Manolis A, Doumas M (2016) Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol . J Hypertens 5:226. doi:10.4172/2167-1095.1000226
Copyright: © 2016 Manolis A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Beta blockers are used for the management of arterial hypertension and are gold standard treatment for coronary artery disease and heart failure, medical conditions that affect large numbers of older patients and are associated with very high morbidity and mortality rates.
Lifelong therapy in primary and secondary prevention (without and with established cardiovascular disease, respectively) is limited by low adherence to drugs which is accompanied by increased mortality. Drug adverse events and impaired quality of life are among the main causes of poor adherence to therapy. Erectile dysfunction is the ‘prima ballerina’ of drug-induced life quality impairment. Beta blockers exert detrimental effects on erectile function. In contrast, nebivolol (a third generation beta blocker with vasodilating properties and proven efficacy in patients with hypertension and heart failure) does not share the unfavourable effects of other beta blockers on erectile function due to increased nitric oxide bioavailability.
Therefore, Nebivolol represents an attractive option for patients with hypertension, heart failure, and other related diseases who need to be treated with beta blockers.